New therapies for treating Down syndrome require quality of life measurement

2013/03/12 by Michael J. Goodman, Diana Brixner · 1 citation
Medicine · #Down syndrome and intellectual disability research

paper · pdf · doi:10.1002/ajmg.a.35705

openalex publication_date 2013/03/12 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28

Abstract

Down syndrome (DS) is the most common genetic cause of cognitive deficits. Using mouse models and therapies for Alzheimer disease, researchers are exploring therapies that may improve cognitive function in people with DS. These developments shift the health economic paradigm of understanding DS from determining the appropriate screening tool to the effect of therapy on quality of life in those with DS. To date, there are no validated quality of life instruments for DS. Research should begin to develop instruments that can evaluate changes in quality of life in therapeutic trials and beyond.

Cited by

• Down syndrome [wikipedia]

Related

• On the Promise of Pharmacotherapies Targeted at Cognitive and Neurodegenerative Components of Down Syndrome
• Down syndrome—A narrative review with a focus on anatomical features
• Eye Tracking as a Tool for Detecting Alzheimer's Disease in People With Down Syndrome
• Clinical practice
• Rivastigmine for dementia in people with Down syndrome